Medivir Nomination Committee appointed

Stockholm, Sweden — Medivir AB (OMX: MVIR) announced that its Nomination
Committee has been appointed. According to an AGM resolution, the Nomination
Committee for the Annual General Meeting 2014 should consist of representatives
for the three largest ranked shareholders, as of the end of the third quarter of
2013, who desire to participate in the Nomination Committee and the Chairman of
the Board.

Work on composing the Nomination Committee is now completed, and this year’s
Nomination Committee consists of: Bo Öberg, founder and A-shareholder, (Bo Öberg
represents through an agreement also the other A- shareholders, Nils Gunnar
Johansson and Christer Sahlberg), Anders Algotson, AFA Försäkring, Annelie
Enquist, Skandia Fonder and Göran Pettersson, Chairman of the Board, Medivir AB.

Shareholders that wish to contact the Nomination Committee can do so by writing
to; Nomination Committee, Medivir AB, Blasieholmsgatan 2, SE-111 48 Stockholm,
Sweden, or via e-mail to; valberedning@medivir.se.

For more information please contact:
Rein Piir, EVP Corporate Affairs & IR
Mobile: +46 708 537 292.


About Medivir
Medivir is an emerging research-based pharmaceutical company focused on
infectious diseases. Medivir has world class expertise in polymerase and
protease drug targets and drug development which has resulted in a strong
infectious disease R&D portfolio. The Company’s key pipeline asset is
simeprevir, a novel protease inhibitor for the treatment of hepatitis C that is
being developed in collaboration with Janssen R&D Ireland. Medivir has also a
broad product portfolio with prescription pharmaceuticals in the Nordics.

For more information about Medivir AB, please visit the Company’s website:
www.medivir.com


Medivir is a collaborative and agile pharmaceutical company with an R&D focus on
infectious diseases and a leading position in hepatitis C. We are passionate and
uncompromising in our mission to develop and commercialize innovative
pharmaceuticals that improve people’s health and quality of life.